Literature DB >> 18812210

Attenuation of ethanol-induced ataxia by alpha(4)beta(2) nicotinic acetylcholine receptor subtype in mouse cerebellum: a functional interaction.

N Taslim1, S Al-Rejaie, M Saeed Dar.   

Abstract

Many epidemiological studies support the notion that people who drink alcohol also smoke cigarettes and vice versa thereby suggesting a possible functional interaction between these two most widely used psychoactive substances. We have earlier demonstrated that direct intracerebellar (ICB) microinfusion of nicotine dose-dependently antagonizes ethanol-induced ataxia and further that this antagonism occurs in a glutamate-nitric oxide-cyclic guanylyl monophosphate (cGMP) sensitive manner. The present study was designed to determine the possible involvement of specific nicotinic acetylcholine receptor (nAChR) subtype alpha(4)beta(2) in nicotine-induced attenuation of ethanol ataxia. Using the Rotorod test and direct ICB microinfusion technique in stereotaxically cannulated CD-1 male mice, we performed the Rotorod test following ICB administration of the alpha(4)beta(2)-selective agonist, (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403; 31.25, 62.5, 125 ng) on ethanol (2 g/kg; i.p.) ataxia at 15, 30, 45, 60 min post-ethanol injection. RJR-2403 dose-dependently attenuated ethanol ataxia suggesting a role of alpha(4)beta(2) subtype in ameliorating ethanol-induced ataxia. Pretreatment with ICB dihydro-beta-erythroidine (DHbetaE: 125, 250, 500, 750 ng), a potent alpha(4)beta(2)-selective antagonist, significantly reduced RJR-2403's effect further supporting the alpha(4)beta(2) involvement. DHbetaE (ICB) also antagonized ICB nicotine-induced attenuation of ethanol ataxia again reinforcing the role of alpha(4)beta(2) subtype. Additional evidence for the role of alpha(4)beta(2) subtype was provided when ICB alpha(4)beta(2) antisense oligodeoxynucleotide treatment markedly antagonized RJR 2403-induced attenuation of ethanol ataxia compared with missense-treated animals. This was confirmed with an associated decrease in the expression of alpha(4)beta(2) subtypes indicated by immunoblot experiments. In conclusion, the results of the present investigation support an important role of alpha(4)beta(2) nAChR subtype in the expression of nicotine-induced attenuation of ethanol ataxia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812210     DOI: 10.1016/j.neuroscience.2008.08.046

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

1.  Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice.

Authors:  Helen M Kamens; Constanza Silva; Colette Peck; Carley N Miller
Journal:  Brain Res Bull       Date:  2017-08-01       Impact factor: 4.077

2.  Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse.

Authors:  Cassandra A Slater; Asti Jackson; Pretal P Muldoon; Anton Dawson; Megan O'Brien; Lindsey G Soll; Rehab Abdullah; F Ivy Carroll; Andrew R Tapper; Michael F Miles; Matthew L Banks; Jill C Bettinger; Imad M Damaj
Journal:  Alcohol Clin Exp Res       Date:  2016-01       Impact factor: 3.455

3.  The α6 nicotinic acetylcholine receptor subunit influences ethanol-induced sedation.

Authors:  Helen M Kamens; Nicole R Hoft; Ryan J Cox; Jill H Miyamoto; Marissa A Ehringer
Journal:  Alcohol       Date:  2012-05-07       Impact factor: 2.405

4.  Decreased Beta(2)*-nicotinic acetylcholine receptor availability after chronic ethanol exposure in nonhuman primates.

Authors:  Kelly P Cosgrove; Tracy Kloczynski; Frederic Bois; Brian Pittman; Gilles Tamagnan; John P Seibyl; John H Krystal; Julie K Staley
Journal:  Synapse       Date:  2010-09       Impact factor: 2.562

5.  Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.

Authors:  C S Lambert; R M Philpot; M E Engberg; B E Johns; L Wecker
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

Review 6.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 7.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

8.  Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study.

Authors:  Elizabeth Ralevski; Edward B Perry; D Cyril D'Souza; Vanessa Bufis; Jacqueline Elander; Diana Limoncelli; Michael Vendetti; Erica Dean; Thomas B Cooper; Sherry McKee; Ismene Petrakis
Journal:  Nicotine Tob Res       Date:  2011-12-16       Impact factor: 4.244

Review 9.  Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.

Authors:  Luis M Tuesta; Christie D Fowler; Paul J Kenny
Journal:  Biochem Pharmacol       Date:  2011-06-29       Impact factor: 5.858

Review 10.  The role of nicotinic acetylcholine receptors in alcohol-related behaviors.

Authors:  C N Miller; H M Kamens
Journal:  Brain Res Bull       Date:  2020-07-22       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.